About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
Biocon Quarterly Results
  > INVESTORS
  Overview
  Corporate Structure
  Corporate Governance
  Company History
  Annual General Meeting
  Postal Ballot
  Investor FAQs
  Stock Info
  Financial Results
  Subsidiary Financials
  Annual Report
  Disclosure to Stock Exchange
  Nomination form
  Press Releases
  Presentations
  Analyst Coverage
  Investor Contacts
  
  
     
 
Financials

Financial Results

 
 
 

Current Financial Year 2018-19

  FY 18-19 Q1 H1 9M FY
  Notice Ad Biocon_Q1 FY18_Press Release - - -
  Press Release Biocon_Q1 FY18_Press Release - - -
  Fact Sheet Biocon_Q1 FY18_Press Release - - -
  Transcript of the Call Biocon_Q1 FY18_Press Release - - -
  Newspaper Advertisement Biocon_Q1 FY18_Press Release - - -
  Results Biocon_Q1 FY18_Press Release - - -
  Investor Presentation Investor Presentation - - -

FINANCIAL HIGHLIGHTS (CONSOLIDATED): Q1FY19

Particulars 

Q1FY19

Q1FY18

Growth

INCOME

Small Molecules

400

363

10%

Biologics

250

184

36%

Branded Formulations

147

130

13%

Research Services

406

291

39%

Inter-segment

(79)

(34)

129%

Revenue from Operations#

1124

934

20%

Other Income

69

54

27%

TOTAL REVENUE

1193

988

21%

EBITDA

307

246

25%

Interest & Finance charges

18

16

9%

Depreciation & Amortisation

99

99

0%

PBT

191

135

41%

Net Profit

120

81

47%

R&D Expenses in P&L

44

58

(24%)

Gross R&D Spends

88

96

(8%)

EBITDA Margin

26%

25%

Core EBITDA Margin

27%

29%

Net Profit Margin

10%

8%

#includes Licensing Income

5

8

(38%)

Year 2017-18 Financial Highlights

In Rs. Crore 
  FY 17-18 Q1 H1 9M FY
  Revenue 988 1019 1092 1237
  EBITDA 246 233 256 300
  Net Profit 81 69 92 130
  R&D Expenses in P&L 58 54 53 51
  Total R&D Spends 96 93 94 98
  EBITDA Margins 25% 23% 23% 24%
  Core EBITDA Margin 29% 27% 27% 26%
  Net Profit Margins 8% 7% 8% 11%
 
  * As per the new accounting standard: Ind-AS  
  FY15-16  FY15-16  FY14-15  FY13-14  FY12-13  FY11-12  FY10-11  FY09-10  FY08-09  FY07-08  FY06-07  FY05-06  FY04-05 

 
Quarterly Results
 FY17-18
 FY16-17
 FY15-16
 FY14-15
 FY13-14
 FY12-13
 FY11-12
 FY10-11
 FY09-10
 FY08-09
 FY07-08
 FY06-07
 FY05-06
 FY04-05
 
 
     
  Biocon

Businesses

Recommended sites Biocon on  
  Home
About Us

Investor Relations
Media Relations
Careers
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Biopharmaceuticals
Research Services
Active Discovery Program

ABLE
Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
       
  Report adverse event/side effects and product complaints    
       
  * Disclaimer            © 2018, Biocon. All Rights Reserved